Close this search box.

ICER released its draft evidence report on beta-amyloid antibodies for early Alzheimer’s disease.

ICER has redefined the scope of this review multiple times since it was first announced over a year ago. Multiple edits to both the timeline and the interventions of interest make meaningful participation in the process difficult.

Read Comments

Leave a Reply

Your email address will not be published. Required fields are marked *